Muscle Atrophy News and Research RSS Feed - Muscle Atrophy News and Research

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

​In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases. [More]
Natural compound from green tomatoes protects against muscle atrophy

Natural compound from green tomatoes protects against muscle atrophy

Using a screening method that previously identified a compound in apple peel as a muscle-boosting agent, a team of University of Iowa scientists has now discovered that tomatidine, a compound from green tomatoes, is even more potent for building muscle and protecting against muscle atrophy. [More]

Scientists honored for orthopedic breakthroughs at 2014 AAOS Annual Meeting

The Kappa Delta Sorority and the Orthopaedic Research and Education Foundation presented four research awards today to scientists who are performing research that translates to improvements in patient treatment and care. [More]

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

Prothelia Incorporated (Prothelia) and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein. [More]
New therapeutic target may help repair muscle damage

New therapeutic target may help repair muscle damage

Researchers at the Stanford University School of Medicine have pinpointed why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury: Over time, stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew. [More]

Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A

Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein. [More]

New orthotic device could aid in rehabilitation of patients with ankle-foot disorders

​A soft, wearable device that mimics the muscles, tendons and ligaments of the lower leg could aid in the rehabilitation of patients with ankle-foot disorders such as drop foot, said Yong-Lae Park, an assistant professor of robotics at Carnegie Mellon University. [More]

University of Barcelona participates in ‘Astronaut Exercise Prescriptions Promoting Health and Fitness on Earth’ project

The University of Barcelona participates in the European project A-fit (Astronaut Exercise Prescriptions Promoting Health and Fitness on Earth), coordinated by the Karolinska Institute (Sweden). It aims at designing a fitness programme to avoid muscle atrophy associated to microgravity. Its results will contribute to the understanding of the beneficial effects of exercise in order to combat the effects of long-term muscle disuse. Findings may be also applied to other research areas, for instance, those diseases characterized by muscular dysfunction. [More]
ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. [More]

Scientists find key gene that activates muscle growth

For decades, scientists have searched for treatments for myopathies - genetic muscular diseases such as muscular dystrophy and ALS, also called Lou Gehrig's disease. [More]
Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting. [More]

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug. [More]
Muscle atrophy therapy: an interview with Dr. Levine, Clinical Associate Professor at Temple University School of Medicine

Muscle atrophy therapy: an interview with Dr. Levine, Clinical Associate Professor at Temple University School of Medicine

Atrophy is loss of muscle which can occur in response to either pain or trauma. When you stop using something like muscle it gets weaker. [More]
Scientists study how oxidative stress in cells impacts sarcopenia in all humans as they age

Scientists study how oxidative stress in cells impacts sarcopenia in all humans as they age

Although muscle cells did not reduce in size or number in mice lacking a protective antioxidant protein, they were weaker than normal muscle cells, researchers from the Barshop Institute for Longevity and Aging Studies at The University of Texas Health Science Center San Antonio found. [More]
New drug target may prevent consequences of ACL tear in athletes

New drug target may prevent consequences of ACL tear in athletes

Striking the likes of Chicago Bulls' Derrick Rose, L.A. Lakers' Kobe Bryant and Detroit Tigers' Victor Martinez, tears in the anterior cruciate ligament (ACL) are one of the most rampant and serious knee injuries among athletes. [More]

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality. [More]
Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life. [More]

Muscle atrophy treatment project to use a SP Scientific LyoStar Freeze Drying System

Using a SP Scientific LyoStar Freeze Drying System - leading pharmaceutical process development experts - GILYOS GmbH (Wuerzburg, Germany) will participate in a research program called "FORMOsA*" which was recently funded with about two million euros by the German Bavarian Research Foundation. The project focuses on age-related muscle atrophy (sarcopenia). [More]

FDA clears Soft Tissue Regeneration’s STR GRAFT

Soft Tissue Regeneration, an early stage orthopedic device company that has developed a breakthrough tissue engineering platform used to regenerate ligaments and tendons, announced today that it has received FDA clearance to market its STR GRAFT, a biodegradable scaffold used for soft tissue augmentation and rotator cuff repair. [More]

Myostatin responsible for initiation of muscle loss: Study

A research study from Nanyang Technological University (NTU) has yielded important breakthroughs on how the body loses muscle, paving the way for new treatments for aging, obesity and diabetes. [More]